Drug Safety Should Focus On “Maximizing Benefit,” Not Just “Minimizing Risk” – FDA’s Goodman
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s acting chief scientist emphasizes need for communication “in the face of uncertainty” and rejects the “either/or” choice of personalized medicine versus comparative effectiveness.
You may also be interested in...
Conspicuous Consumption: TB Therapies Are A Priority At FDA
A June 3 advisory committee discussion of tuberculosis drug development offers a good early case study of how the Hamburg FDA may benefit some classes of drug development
Conspicuous Consumption: TB Therapies Are A Priority At FDA
A June 3 advisory committee discussion of tuberculosis drug development offers a good early case study of how the Hamburg FDA may benefit some classes of drug development
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute